STAB News and Press, Statera Biopharma Inc. From 02/22/22

Statera Biopharma (NASDAQ:STAB), formerly known as "Cytocom," has reported prelim revenue of $1.49M for 2021. The biopharmaceutical firm reported no revenue in 2020. The growth in revenue was attributed to the acquisition of ImQuest Life Sciences and its subsidiaries by Cytocom in June 2021. ...

FORT COLLINS, Colo., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasi...

STAT-201 is being developed as a novel, immune-modulation therapy for treating Crohn’s Disease Phase 3 trial expected to begin in second quarter 2022 FORT COLLINS, Colo., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (Nasdaq: STAB), a leading bio...

FORT COLLINS, Colo., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasi...

Gainers Bakkt Holdings (NYSE:BKKT) +30%. Kaival Brands Innovations Group (NASDAQ:KAVL) +29%. CF Acquisition (NASDAQ:CFVIU) +21%. CF Acquisition (NASDAQ:CFVI) +19%. Origin Agritech (NASDAQ:SEED) +20%. Phunware (NASDAQ:PHUN) +19%. IceCure Medical (NASDAQ:ICCM) +17%. Peloton Interactive (NASDAQ:...

Gainers: IceCure Medical (NASDAQ:ICCM) +16%. Atossa Therapeutics (NASDAQ:ATOS) +15%. G Medical Innovations (NASDAQ:GMVD) +11%. Exscientia (NASDAQ:EXAI) +10%. Immix Biopharma (NASDAQ:IMMX) +10%. Losers: Dermata Therapeutics (NASDAQ:DRMA) -...

Statera Biopharma (NASDAQ:STAB) slumps 19.1% premarket Monday after the firm enters into a securities purchase agreement with a certain institutional investor to purchase ~$2.0M worth of its common stock and warrants in a registered direct offering. Under the terms, the Company has agree...

FORT COLLINS, Colo., Feb. 06, 2022 (GLOBE NEWSWIRE) -- Statera Biopharma, Inc. (NASDAQ: STAB) (the “Company” or “Statera Biopharma”), a leading biopharmaceutical company creating next-generation immune therapies that focus on immune restoration and homeostasi...

AAP, ACTG, AESE, OTCPK:AOIFF, DADAASTS, ATHX, AXON, AYTU, BIOC, BITF, CIDM, CMP, OTCQX:CWBHF, CWBR, CWCO, CYBN, DM, DNMR, DRIO, OTCQB:ELTP, ETON, EVFM, GLAD, GNLN, GOEV, IBIO, IDEX, INPX, IONQ, ISUN, LCID, LUNA, MARK, OTCQX:MRMD, MVST, NDRA, NEPT, PLBY, POWW, PRCH, PRPO, QFIN, RKDA,...

Statera Biopharma (NASDAQ:STAB) soars 10.2% premarket after submitting its Phase 3 clinical trial protocol for STAT-201 in the treatment of pediatric Crohn’s Disease (CD) to the FDA. The Phase 3 trial will evaluate the safety and efficacy of STAT-201 compared to placebo ...